Swiss perspectives in 10 languages

Lausanne hospital test chosen for coronavirus study 

blood sample
The CHUV blood test will be used for wide-scale coronavirus antibody studies across Switzerland. © Keystone / Christian Beutler

A Covid-19 antibody test developed at Lausanne university hospital (CHUV) has been chosen for wide-scale studies of the Swiss population, the hospital has announced. 

Selection of a single serology test was necessary for consistent and comparable data at national level, CHUV said on Thursday.  

The hospital announced in June that one of its teams had developed a new coronavirus antibody blood test in collaboration with the Federal Institute of Technology Lausanne (EPFL) and the Swiss Vaccine Research Institute.  

“Compared to other commercially available tests, the technology developed at the CHUV has a 15-30% higher sensitivity, making it possible to detect antibodies to SARS-CoV-2 long after infection, even in people with few or no symptoms,” CHUV said in a press release. 

Corona Immunitas, the government-backed antibody testing programme, has now chosen it for nationwide tests. Supported by the Federal Office of Public Health (FOPH), Corona Immunitas is in charge of coordinating more than 20 population studies to estimate the number of people infected with SARS-CoV-2 in Switzerland.  

Such studies are very useful from an epidemiological point of view and may also help determine immunity levels to the virus.  


Popular Stories

Most Discussed

News

Two men charged by the MPC with money laundering

More

Two Swiss men charged with money laundering

This content was published on One million francs, 34 million euros and around 830 kilos of gold: this is the fortune that two Swiss nationals are accused of having moved across borders for at least four years.

Read more: Two Swiss men charged with money laundering
Richemont reports lower first-half results

More

Richemont reports lower first-half results

This content was published on Geneva-based luxury goods group Richemont reported a downturn in performance for the first half of its 2024/25 financial year. Both sales and profit declined.

Read more: Richemont reports lower first-half results

In compliance with the JTI standards

More: SWI swissinfo.ch certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here . Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR